Hot Stocks: Brokerages on Orchid Pharma, D-Mart, NOCIL and Chola Investment

December 8, 2023

Investec maintained a buy rating on Orchid Pharma with a target price of Rs 800. The company is set for strong growth over the next 3 years. The new management continues to execute the turnaround strategy well. It sees a strong 35%+ EBITDA CAGR over FY23-26 for the base biz (ex-PLI).

More To Explore

Gautam Duggad sees PE re-rating potential in 2 sectors; likes largecaps & may raise weight in Reliance

Gautam Duggal, Head of Research at Motilal Oswal, sees limited PE re-rating potential, primarily in large-cap financials and capital market stocks. He favors earnings visibility

December 23, 2024

Sebi halts trading in Bharat Global Developers shares amid suspicious price surge

Bharat Global Developers’ shares fell 5% after SEBI suspended trading and banned promoters due to concerns over financial disclosures. The company’s stock surged 2,304% in

December 23, 2024

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003